Just how good an investment is the biopharmaceutical sector?: https://t.co/01Fui2blgh via @BraincuresLTD #socent #socialimpact
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
In a nutshell, the risk that large drug companies would have diverse fortunes, so evident in the 1970s, disappeared completely after 1980. They all do well. [...] Investing at the [pharma] company level is a good, solid, and basically riskless proposition
Given the the large amount of systematic & idiosyncratic risk in biotech, the typical response of investors is to reduce the amount of venture capital investments in #biotech. Such a response may be one financial cause of the valley of death in biomedi
One possibility is to change the business and financing structure of the biomedical industry. Adopting a more dynamic project-oriented approach to #biomedical innovation—along the lines of Hollywood film studios—can improve efficiency and reduce costs #RRI
In the United States, the biopharmaceutical sector accounted for 854,000 jobs, $150 billion in total wages & benefits, and 3.8% of total US output in 2014. However, investment capital in this industry has waxed & waned over time in response to many
Thakor @yuweizhang_ @AndrewWLo et al find that the performance of the biotech sector is highly sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high stock volatility
RT @paras_biotech: 1980 to 2015, the annualized return & sharpe ratio of the pharma sector was higher than the market, but biotech not so m…
$1 invested in pharma companies at the beginning of 1980 would be worth roughly $114 at the end of 2015, whereas: $1 invested in the market in 1980 would be worth $44 $1 invested in biotech companies in 1980 would be worth only about $8 -Richard Thakor @yu
RT @paras_biotech: 1980 to 2015, the annualized return & sharpe ratio of the pharma sector was higher than the market, but biotech not so m…
RT @paras_biotech: 1980 to 2015, the annualized return & sharpe ratio of the pharma sector was higher than the market, but biotech not so m…
1980 to 2015, the annualized return & sharpe ratio of the pharma sector was higher than the market, but biotech not so much (though biotech is the feeder of novel drugs to pharma) *Sharpe ratio: a measure of an investment’s return/unit of total risk
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
RT @spane_org: Just how good an investment is the biopharmaceutical sector?: https://t.co/01Fui2soih courtesy of @BraincuresLTD #socent #im…
Just how good an investment is the biopharmaceutical sector?: https://t.co/01Fui2soih courtesy of @BraincuresLTD #socent #impinv
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
RT @BraincuresLTD: This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000…
This @NatureBiotech article tracked the performance of 1,066 #biopharmaceutical companies from 1930 to 2015 Since 2000 #pharmaceutical companies have given returns that consistently outperformed the #market #bioinvestors #SocEnt #biobankers #IoT #ImpInv
RT @RLLF77: No solo existe un alto riesgo intrínseco, los riesgos económicos sistémicos son también importantes. Solo existe un camino, el…
No solo existe un alto riesgo intrínseco, los riesgos económicos sistémicos son también importantes. Solo existe un camino, el conocimiento profundo del medio #biotech #medtech #digitalhealth #angelinvestor #venturecapital #corporateventure @biocrewinvest
"Since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market" #profitability #drug #pharmaceuticalindustry https://t.co/58jrxcrrpU
https://t.co/MxO0B59sCE #MCECONHE @kompalsinha
Just how good an investment is the biopharmaceutical sector? 💊💉https://t.co/5V4O68qToc
Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies poses a challenge to those interested in funding such enterprises. https://t.co/9ZmLa9xOPT
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
RT @AndrewWLo: Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one ind…
Pls see my new pub on risk and reward in biotech and pharma (https://t.co/c934t7T3S7); like an enzyme and substrate, one industry is catalyst for the other, both are critical. Better financing and business models can lower costs and bring therapies to pati
RT @OscarALizarazo: "In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns cons…
RT @NatureBiotech: Just how good an investment is the biopharmaceutical sector? https://t.co/PdmuqjbisB #drugdevelopment #healthcareeconomi…
RT @NatureBiotech: Just how good an investment is the biopharmaceutical sector? https://t.co/PdmuqjbisB #drugdevelopment #healthcareeconomi…
One for @BiotechPolicyUK ... https://t.co/pxPuy9N3we
RT @NatureBiotech: Just how good an investment is the biopharmaceutical sector? https://t.co/PdmuqjbisB #drugdevelopment #healthcareeconomi…
"In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk-adjusted returns consistently outperforming the market" https://t.co/4scco75BsM
Just how good an investment is the biopharmaceutical sector? https://t.co/PdmuqjbisB #drugdevelopment #healthcareeconomics https://t.co/APwc9IqXVx
RT @WildImmunity: #BigPharma is perennial winner for investors. #Startups are high risk and unlikely to reward (i.e. gambling) https://t.co…
#BigPharma is perennial winner for investors. #Startups are high risk and unlikely to reward (i.e. gambling) https://t.co/pRWh3cu8QC
How good an investment is biopharma? Insightful paper from my Carlson Finance colleague Richard Thakor https://t.co/uU53OxumAt @CarlsonMILI
RT @ATCGPartners: Another view of #drugRandD: profitability of biopharma vs biotech and compared with tech @NatureBiotech https://t.co/2geM…
Another view, same conclusion https://t.co/rUR3KxhzDv
RT @ATCGPartners: Another view of #drugRandD: profitability of biopharma vs biotech and compared with tech @NatureBiotech https://t.co/2geM…
Another view of #drugRandD: profitability of biopharma vs biotech and compared with tech @NatureBiotech https://t.co/2geMxcYi9t https://t.co/JbWRxRa6HR
Just how good an investment is the biopharmaceutical sector? https://t.co/CMyX9FAW6N https://t.co/D7g1GsA7yh